Header Logo

Connection

KENNETH R HESS to Middle Aged

Back to Details
This is a "connection" page, showing publications KENNETH R HESS has written about Middle Aged.
KENNETH R HESS
Connection Strength
0.807
Middle Aged
  1. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203.
    View in: PubMed
    Score: 0.018
  2. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):449-55.
    View in: PubMed
    Score: 0.017
  3. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44.
    View in: PubMed
    Score: 0.011
  4. Metastatic patterns in adenocarcinoma. Cancer. 2006 Apr 01; 106(7):1624-33.
    View in: PubMed
    Score: 0.011
  5. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol. 2006 May; 78(1):85-90.
    View in: PubMed
    Score: 0.010
  6. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004 Nov 15; 101(10):2293-9.
    View in: PubMed
    Score: 0.010
  7. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003 04; 5(2):89-95.
    View in: PubMed
    Score: 0.009
  8. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003 Mar; 78(1):105-18.
    View in: PubMed
    Score: 0.009
  9. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000 Oct; 6(10):3878-84.
    View in: PubMed
    Score: 0.007
  10. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
    View in: PubMed
    Score: 0.007
  11. Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. Br J Cancer. 2020 10; 123(9):1417-1423.
    View in: PubMed
    Score: 0.007
  12. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 2020 May 18; 20(1):430.
    View in: PubMed
    Score: 0.007
  13. Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1).
    View in: PubMed
    Score: 0.007
  14. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
    View in: PubMed
    Score: 0.007
  15. The role of magnetic resonance imaging in patients with palpable breast abnormalities and negative mammographic and sonographic findings. Breast J. 2020 07; 26(7):1289-1295.
    View in: PubMed
    Score: 0.007
  16. Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Support Palliat Care. 2021 Jun; 11(2):170-179.
    View in: PubMed
    Score: 0.007
  17. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
    View in: PubMed
    Score: 0.007
  18. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999 Nov; 5(11):3403-10.
    View in: PubMed
    Score: 0.007
  19. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604.
    View in: PubMed
    Score: 0.007
  20. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
    View in: PubMed
    Score: 0.007
  21. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273.
    View in: PubMed
    Score: 0.007
  22. Response and progression in recurrent malignant glioma. Neuro Oncol. 1999 10; 1(4):282-8.
    View in: PubMed
    Score: 0.007
  23. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.007
  24. Somatotopy and Organization of Spinothalamic Tracts in the Human Cervical Spinal Cord. Neurosurgery. 2019 06 01; 84(6):E311-E317.
    View in: PubMed
    Score: 0.007
  25. Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center. Ann Surg Oncol. 2019 Oct; 26(11):3593-3599.
    View in: PubMed
    Score: 0.007
  26. Not all patients with a diagnosis of a radial scar require excision. Breast J. 2019 07; 25(4):792-794.
    View in: PubMed
    Score: 0.007
  27. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019 Jul; 176(1):227-234.
    View in: PubMed
    Score: 0.006
  28. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348.
    View in: PubMed
    Score: 0.006
  29. Minimally Invasive Cordotomy for Refractory Cancer Pain: A Randomized Controlled Trial. Oncologist. 2019 07; 24(7):e590-e596.
    View in: PubMed
    Score: 0.006
  30. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351.
    View in: PubMed
    Score: 0.006
  31. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.
    View in: PubMed
    Score: 0.006
  32. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.
    View in: PubMed
    Score: 0.006
  33. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
    View in: PubMed
    Score: 0.006
  34. High risk breast lesions identified on MRI-guided vacuum-assisted?needle?biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol. 2018 Oct; 91(1090):20180300.
    View in: PubMed
    Score: 0.006
  35. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
    View in: PubMed
    Score: 0.006
  36. An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology. 2018 10; 96:109-117.
    View in: PubMed
    Score: 0.006
  37. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.006
  38. Imaging of Intracystic Papillary Carcinoma. Curr Probl Diagn Radiol. 2019 Jul - Aug; 48(4):348-352.
    View in: PubMed
    Score: 0.006
  39. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncol. 2018 Apr 12; 4(4):e175092.
    View in: PubMed
    Score: 0.006
  40. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
    View in: PubMed
    Score: 0.006
  41. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
    View in: PubMed
    Score: 0.006
  42. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87.
    View in: PubMed
    Score: 0.006
  43. Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy. J Neurooncol. 2018 Mar; 137(1):57-65.
    View in: PubMed
    Score: 0.006
  44. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2253-61.
    View in: PubMed
    Score: 0.006
  45. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
    View in: PubMed
    Score: 0.006
  46. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.
    View in: PubMed
    Score: 0.006
  47. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017 10; 125(1):80-88.
    View in: PubMed
    Score: 0.006
  48. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw. 2017 09; 15(9):1111-1120.
    View in: PubMed
    Score: 0.006
  49. Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clin Exp Metastasis. 2017 06; 34(5):315-322.
    View in: PubMed
    Score: 0.006
  50. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589.
    View in: PubMed
    Score: 0.006
  51. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048.
    View in: PubMed
    Score: 0.006
  52. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017 06 01; 19(6):786-795.
    View in: PubMed
    Score: 0.006
  53. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 2017 05 01; 19(5):660-668.
    View in: PubMed
    Score: 0.006
  54. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.006
  55. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
    View in: PubMed
    Score: 0.006
  56. Effect of Mammography on Marker Clip Migration After Stereotactic-Guided Core Needle Breast Biopsy. Curr Probl Diagn Radiol. 2017 Nov - Dec; 46(6):410-414.
    View in: PubMed
    Score: 0.006
  57. Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up. AJR Am J Roentgenol. 2017 Apr; 208(4):916-922.
    View in: PubMed
    Score: 0.006
  58. Use of Spinal Cord Diffusion Tensor Imaging to Quantify Neural Ablation and Evaluate Outcome after Percutaneous Cordotomy for Intractable Cancer Pain. Stereotact Funct Neurosurg. 2017; 95(1):34-39.
    View in: PubMed
    Score: 0.006
  59. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289.
    View in: PubMed
    Score: 0.006
  60. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
    View in: PubMed
    Score: 0.005
  61. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.
    View in: PubMed
    Score: 0.005
  62. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.
    View in: PubMed
    Score: 0.005
  63. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
    View in: PubMed
    Score: 0.005
  64. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71.
    View in: PubMed
    Score: 0.005
  65. Incidental Suspicious Regional Lymph Nodes on Breast Sonography: Is Sampling Necessary? Curr Probl Diagn Radiol. 2017 Mar - Apr; 46(2):100-104.
    View in: PubMed
    Score: 0.005
  66. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
    View in: PubMed
    Score: 0.005
  67. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52.
    View in: PubMed
    Score: 0.005
  68. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.
    View in: PubMed
    Score: 0.005
  69. Development of a model to predict breast cancer survival using data from the National Cancer Data Base. Surgery. 2016 Feb; 159(2):495-502.
    View in: PubMed
    Score: 0.005
  70. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41.
    View in: PubMed
    Score: 0.005
  71. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
    View in: PubMed
    Score: 0.005
  72. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
    View in: PubMed
    Score: 0.005
  73. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol. 2015 May; 123(1):141-50.
    View in: PubMed
    Score: 0.005
  74. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015 May; 20(5):466-73.
    View in: PubMed
    Score: 0.005
  75. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):349-57.
    View in: PubMed
    Score: 0.005
  76. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54.
    View in: PubMed
    Score: 0.005
  77. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.
    View in: PubMed
    Score: 0.005
  78. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46.
    View in: PubMed
    Score: 0.005
  79. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.
    View in: PubMed
    Score: 0.005
  80. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.
    View in: PubMed
    Score: 0.005
  81. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9.
    View in: PubMed
    Score: 0.005
  82. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22.
    View in: PubMed
    Score: 0.005
  83. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
    View in: PubMed
    Score: 0.005
  84. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8.
    View in: PubMed
    Score: 0.005
  85. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol. 2014 Jun; 16(6):823-8.
    View in: PubMed
    Score: 0.005
  86. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 2014 Mar; 19(3):228-34.
    View in: PubMed
    Score: 0.005
  87. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol. 2014 Jan; 25(1):276-82.
    View in: PubMed
    Score: 0.005
  88. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014 Jan; 16(1):81-91.
    View in: PubMed
    Score: 0.004
  89. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):591-9.
    View in: PubMed
    Score: 0.004
  90. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013 Apr; 71(4):955-63.
    View in: PubMed
    Score: 0.004
  91. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
    View in: PubMed
    Score: 0.004
  92. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6.
    View in: PubMed
    Score: 0.004
  93. Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary. 2012 Dec; 15(4):556-61.
    View in: PubMed
    Score: 0.004
  94. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606.
    View in: PubMed
    Score: 0.004
  95. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol. 2012 Apr; 36(2):206-11.
    View in: PubMed
    Score: 0.004
  96. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog. 2012 Jun; 51(6):491-9.
    View in: PubMed
    Score: 0.004
  97. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67.
    View in: PubMed
    Score: 0.004
  98. Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev Res (Phila). 2011 May; 4(5):758-66.
    View in: PubMed
    Score: 0.004
  99. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist. 2011; 16(1):61-70.
    View in: PubMed
    Score: 0.004
  100. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer. 2011 Feb 01; 117(3):480-91.
    View in: PubMed
    Score: 0.004
  101. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61.
    View in: PubMed
    Score: 0.004
  102. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010 Aug; 139(2):464-73, 473.e1-3.
    View in: PubMed
    Score: 0.003
  103. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
    View in: PubMed
    Score: 0.003
  104. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov; 10(11):1037-44.
    View in: PubMed
    Score: 0.003
  105. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009 Sep; 94(2):229-34.
    View in: PubMed
    Score: 0.003
  106. Prediction of left ventricular ejection fraction using a unique method of chest x-ray and ECG analysis: a noninvasive index of cardiac performance based on the concept of heart volume and mass interrelationship. Am Heart J. 1989 Mar; 117(3):590-8.
    View in: PubMed
    Score: 0.003
  107. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14.
    View in: PubMed
    Score: 0.003
  108. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009 Apr 01; 27(10):1592-9.
    View in: PubMed
    Score: 0.003
  109. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15; 113(8):2046-52.
    View in: PubMed
    Score: 0.003
  110. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008 Sep 20; 26(27):4442-8.
    View in: PubMed
    Score: 0.003
  111. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008 Dec; 10(6):1010-8.
    View in: PubMed
    Score: 0.003
  112. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008 Oct; 90(1):89-97.
    View in: PubMed
    Score: 0.003
  113. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23.
    View in: PubMed
    Score: 0.003
  114. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008 Apr; 10(2):208-15.
    View in: PubMed
    Score: 0.003
  115. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22.
    View in: PubMed
    Score: 0.003
  116. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1275-81.
    View in: PubMed
    Score: 0.003
  117. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90.
    View in: PubMed
    Score: 0.003
  118. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6603-9.
    View in: PubMed
    Score: 0.003
  119. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007 Aug; 189(2):378-85.
    View in: PubMed
    Score: 0.003
  120. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40.
    View in: PubMed
    Score: 0.003
  121. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80.
    View in: PubMed
    Score: 0.003
  122. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7.
    View in: PubMed
    Score: 0.003
  123. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006 Sep 01; 24(25):4107-15.
    View in: PubMed
    Score: 0.003
  124. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage. 2006 Aug; 32(2):148-54.
    View in: PubMed
    Score: 0.003
  125. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol. 2006 Apr 01; 24(10):1627-32.
    View in: PubMed
    Score: 0.003
  126. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93.
    View in: PubMed
    Score: 0.003
  127. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006 Apr 10; 24(11):1720-8.
    View in: PubMed
    Score: 0.003
  128. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9.
    View in: PubMed
    Score: 0.003
  129. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16):5678-85.
    View in: PubMed
    Score: 0.003
  130. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61.
    View in: PubMed
    Score: 0.003
  131. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn. 2005 Aug; 7(3):357-67.
    View in: PubMed
    Score: 0.003
  132. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103.
    View in: PubMed
    Score: 0.002
  133. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35.
    View in: PubMed
    Score: 0.002
  134. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs. 2004 Nov; 22(4):459-66.
    View in: PubMed
    Score: 0.002
  135. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9.
    View in: PubMed
    Score: 0.002
  136. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol. 2004 Jul; 6(3):253-8.
    View in: PubMed
    Score: 0.002
  137. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun; 239(6):818-25; discussion 825-7.
    View in: PubMed
    Score: 0.002
  138. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
    View in: PubMed
    Score: 0.002
  139. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer. 2004 Apr 15; 100(8):1712-6.
    View in: PubMed
    Score: 0.002
  140. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1994 Mar 01; 73(5):1533-5.
    View in: PubMed
    Score: 0.002
  141. O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol. 2004 Jan; 6(1):28-32.
    View in: PubMed
    Score: 0.002
  142. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):33-7.
    View in: PubMed
    Score: 0.002
  143. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54.
    View in: PubMed
    Score: 0.002
  144. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
    View in: PubMed
    Score: 0.002
  145. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71.
    View in: PubMed
    Score: 0.002
  146. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003 Jun 15; 21(12):2305-11.
    View in: PubMed
    Score: 0.002
  147. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res. 2003 Mar; 9(3):981-90.
    View in: PubMed
    Score: 0.002
  148. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology. 2003; 65(3):259-66.
    View in: PubMed
    Score: 0.002
  149. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002 Sep 15; 20(18):3792-803.
    View in: PubMed
    Score: 0.002
  150. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002 Sep 15; 20(18):3804-14.
    View in: PubMed
    Score: 0.002
  151. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
    View in: PubMed
    Score: 0.002
  152. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002 Sep 01; 95(5):1120-6.
    View in: PubMed
    Score: 0.002
  153. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 2002 May 01; 53(1):58-66.
    View in: PubMed
    Score: 0.002
  154. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol. 2002 Apr; 4(2):109-14.
    View in: PubMed
    Score: 0.002
  155. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002 Mar 01; 20(5):1383-8.
    View in: PubMed
    Score: 0.002
  156. Spinal cord protection during aortic cross clamping: retrograde venous spinal cord perfusion, distal aortic perfusion, and cerebrospinal fluid drainage. Scand Cardiovasc J. 2002 Feb; 36(1):6-10.
    View in: PubMed
    Score: 0.002
  157. Expression of metastasis-related genes in human epithelial ovarian tumors. Int J Oncol. 2002 Jan; 20(1):5-13.
    View in: PubMed
    Score: 0.002
  158. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002; 20(7-8):948-54.
    View in: PubMed
    Score: 0.002
  159. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12.
    View in: PubMed
    Score: 0.002
  160. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001 Aug; 95(2):190-8.
    View in: PubMed
    Score: 0.002
  161. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg. 2001 Jul; 234(1):47-55.
    View in: PubMed
    Score: 0.002
  162. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol. 2001 07; 3(3):167-73.
    View in: PubMed
    Score: 0.002
  163. Surgery for abdominal metastases of cutaneous melanoma. World J Surg. 2001 Jun; 25(6):750-8.
    View in: PubMed
    Score: 0.002
  164. Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer. 2001 Feb 15; 91(4):815-21.
    View in: PubMed
    Score: 0.002
  165. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol. 2000 Nov; 17(5):963-9.
    View in: PubMed
    Score: 0.002
  166. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol. 2000 Oct 01; 18(19):3378-83.
    View in: PubMed
    Score: 0.002
  167. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000 Feb; 18(3):646-50.
    View in: PubMed
    Score: 0.002
  168. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1999 Aug 01; 45(1):127-35.
    View in: PubMed
    Score: 0.002
  169. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999 Aug; 17(8):2572-8.
    View in: PubMed
    Score: 0.002
  170. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg. 1999 May-Jun; 3(3):263-77.
    View in: PubMed
    Score: 0.002
  171. Gamma-ray mutagen sensitivity and survival in patients with glioma. Clin Cancer Res. 1998 Dec; 4(12):3031-5.
    View in: PubMed
    Score: 0.002
  172. Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1998 Oct; 40(1):51-7.
    View in: PubMed
    Score: 0.002
  173. Cancer among a Michigan cohort exposed to polybrominated biphenyls in 1973. Epidemiology. 1998 Jul; 9(4):373-8.
    View in: PubMed
    Score: 0.002
  174. Reduction of neurologic injury after high-risk thoracoabdominal aortic operation. Ann Thorac Surg. 1998 Jul; 66(1):132-8.
    View in: PubMed
    Score: 0.002
  175. Unknown primary tumors metastatic to liver. J Clin Oncol. 1998 Jun; 16(6):2105-12.
    View in: PubMed
    Score: 0.002
  176. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998 May; 42(5):1044-55; discussion 1055-6.
    View in: PubMed
    Score: 0.002
  177. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology. 1998 Mar; 50(3):777-81.
    View in: PubMed
    Score: 0.002
  178. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. 1997 Oct; 3(10):1685-90.
    View in: PubMed
    Score: 0.001
  179. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997 May 12; 157(9):970-6.
    View in: PubMed
    Score: 0.001
  180. Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Surgery. 1997 May; 121(5):479-87.
    View in: PubMed
    Score: 0.001
  181. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol. 1997 May; 15(5):2056-66.
    View in: PubMed
    Score: 0.001
  182. Evaluation of sister chromatid exchange and chromosome breaks in a cohort of untreated Hodgkin's disease patients. Cancer Epidemiol Biomarkers Prev. 1997 Apr; 6(4):291-3.
    View in: PubMed
    Score: 0.001
  183. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70.
    View in: PubMed
    Score: 0.001
  184. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res. 1996 Sep; 2(9):1489-97.
    View in: PubMed
    Score: 0.001
  185. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1995 Dec; 1(12):1617-22.
    View in: PubMed
    Score: 0.001
  186. Reoperation for recurrent metastatic brain tumors. J Neurosurg. 1995 Oct; 83(4):600-4.
    View in: PubMed
    Score: 0.001
  187. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995 Aug; 13(8):2094-103.
    View in: PubMed
    Score: 0.001
  188. Aggressive meningeal tumors: review of a series. J Neurosurg. 1995 Jan; 82(1):17-27.
    View in: PubMed
    Score: 0.001
  189. Influence of segmental arteries, extent, and atriofemoral bypass on postoperative paraplegia after thoracoabdominal aortic operations. J Vasc Surg. 1994 Aug; 20(2):255-62.
    View in: PubMed
    Score: 0.001
  190. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994 Jun; 12(6):1272-80.
    View in: PubMed
    Score: 0.001
  191. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol. 1994 Jan; 1(1):73-8.
    View in: PubMed
    Score: 0.001
  192. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993 May 15; 71(10):3119-23.
    View in: PubMed
    Score: 0.001
  193. Percutaneous transluminal coronary angioplasty utilizing prolonged balloon inflations: initial results and six-month follow-up. Cathet Cardiovasc Diagn. 1991 Aug; 23(4):239-44.
    View in: PubMed
    Score: 0.001
  194. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J Vasc Surg. 1986 Mar; 3(3):389-404.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.